Basel, April 11, 2022 — Novartis today announced promising clinical data for JDQ443, an investigational selective, covalent, and orally bioavailable KRASG12C inhibitor at the annual meeting of American Association for Cancer Research (AACR).
Comprehensive information on the discovery of JDQ443 is also included in a poster being presented on Wednesday 13th April with further details published in the journal Cancer Discovery.
โฆษณา
- ดาวน์โหลดแอปพลิเคชัน
- © 2024 Blockdit
